| Molecular formula | C45H55N9O6 |
|---|
| Molecular weight | 818 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 6918245 |
|---|
What Pralmorelin Is
Pralmorelin is a synthetic peptide compound with the molecular formula C45H55N9O6 and a molecular weight of approximately 818 g/mol (PubChem CID 6918245). It has no FDA-approved label, no approved brand name, and no established medical indication in the United States. Any use of pralmorelin outside of formal research settings falls outside its current regulatory status.
Trial Footprint
Publicly registered clinical trial databases show no currently listed trials for pralmorelin. This means there is no clinical trial activity to summarize at this time. As a research-stage compound, any future data on human studies would need to be drawn from registries as they are updated.
FAQ
No. Pralmorelin does not have an FDA-approved label, an approved brand name, or an approved medical indication. It is classified as an unapproved research compound.
Pralmorelin is a synthetic peptide with the molecular formula C45H55N9O6 and a molecular weight of about 818 g/mol. It is identified in PubChem under CID 6918245.
Current registry data shows no clinical trials listed for pralmorelin. This does not rule out future research, but no trial activity is documented at this time.
No adverse event reports or safety data are currently available for pralmorelin in the datasets reviewed. This reflects a lack of reported data rather than a confirmation of safety.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 6918245 ClinicalTrials.gov registry search
Updated 2026-08-03